JP4740114B2 - クロメノンインドール - Google Patents

クロメノンインドール Download PDF

Info

Publication number
JP4740114B2
JP4740114B2 JP2006504582A JP2006504582A JP4740114B2 JP 4740114 B2 JP4740114 B2 JP 4740114B2 JP 2006504582 A JP2006504582 A JP 2006504582A JP 2006504582 A JP2006504582 A JP 2006504582A JP 4740114 B2 JP4740114 B2 JP 4740114B2
Authority
JP
Japan
Prior art keywords
formula
compound
group
butyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006504582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006522034A (ja
JP2006522034A5 (enExample
Inventor
カイ シーマン，
ヘニンク ベットヒェル，
ティモ ハインリッヒ，
グンター ヘルツェマン，
アムステルダム， クリストフ ヴァン
ゲルト バルトツィク，
ヨアヒム ライブロック，
クリストフ ゼイフリート，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2006522034A publication Critical patent/JP2006522034A/ja
Publication of JP2006522034A5 publication Critical patent/JP2006522034A5/ja
Application granted granted Critical
Publication of JP4740114B2 publication Critical patent/JP4740114B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
JP2006504582A 2003-04-04 2004-03-08 クロメノンインドール Expired - Fee Related JP4740114B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10315285A DE10315285A1 (de) 2003-04-04 2003-04-04 Chromenonindole
DE10315285.7 2003-04-04
PCT/EP2004/002351 WO2004087692A1 (de) 2003-04-04 2004-03-08 Chromenonindole

Publications (3)

Publication Number Publication Date
JP2006522034A JP2006522034A (ja) 2006-09-28
JP2006522034A5 JP2006522034A5 (enExample) 2007-04-26
JP4740114B2 true JP4740114B2 (ja) 2011-08-03

Family

ID=32981019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006504582A Expired - Fee Related JP4740114B2 (ja) 2003-04-04 2004-03-08 クロメノンインドール

Country Status (18)

Country Link
US (1) US7968551B2 (enExample)
EP (1) EP1611126B1 (enExample)
JP (1) JP4740114B2 (enExample)
KR (1) KR20050119673A (enExample)
CN (1) CN1768056A (enExample)
AR (1) AR043834A1 (enExample)
AT (1) ATE446959T1 (enExample)
AU (1) AU2004226279B2 (enExample)
BR (1) BRPI0408467A (enExample)
CA (1) CA2520892C (enExample)
DE (2) DE10315285A1 (enExample)
DK (1) DK1611126T3 (enExample)
ES (1) ES2335665T3 (enExample)
MX (1) MXPA05010483A (enExample)
PL (2) PL377730A1 (enExample)
PT (1) PT1611126E (enExample)
WO (1) WO2004087692A1 (enExample)
ZA (1) ZA200508922B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
CN103304547A (zh) * 2012-03-13 2013-09-18 中国药科大学 一种抗抑郁药维拉唑酮的制备方法
CN104045608B (zh) * 2013-03-11 2016-06-01 天津药物研究院有限公司 一种取代哌嗪化合物及制备维拉佐酮中间体的方法
CN104059046B (zh) * 2013-03-18 2017-02-08 江苏恩华药业股份有限公司 黄酮类衍生物及其应用
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
US10316025B2 (en) 2015-06-03 2019-06-11 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
DE19730989A1 (de) 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate

Also Published As

Publication number Publication date
DK1611126T3 (da) 2010-01-18
CA2520892C (en) 2012-08-21
EP1611126A1 (de) 2006-01-04
WO2004087692A1 (de) 2004-10-14
ATE446959T1 (de) 2009-11-15
PL377730A1 (pl) 2006-02-06
US7968551B2 (en) 2011-06-28
AU2004226279B2 (en) 2010-10-28
PT1611126E (pt) 2010-01-29
BRPI0408467A (pt) 2006-04-04
KR20050119673A (ko) 2005-12-21
CN1768056A (zh) 2006-05-03
MXPA05010483A (es) 2005-11-16
ZA200508922B (en) 2007-02-28
JP2006522034A (ja) 2006-09-28
DE10315285A1 (de) 2004-10-14
EP1611126B1 (de) 2009-10-28
CA2520892A1 (en) 2004-10-14
ES2335665T3 (es) 2010-03-31
PL1611126T3 (pl) 2010-02-26
AR043834A1 (es) 2005-08-17
DE502004010296D1 (de) 2009-12-10
US20060258680A1 (en) 2006-11-16
AU2004226279A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
KR100528684B1 (ko) 피페라진 유도체
JP4065034B2 (ja) ピペリジン類およびピペラジン類
CA2428039C (en) Serotonergic agents
JP4740114B2 (ja) クロメノンインドール
AU2002237654A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
WO2011002103A2 (en) A cycloalkane derivative
AU2004249372B2 (en) Indole derivatives as serotonin reuptake inhibitors
KR20010013750A (ko) 3-벤질피페리딘
JP2006527706A (ja) セロトニン再取り込み阻害剤としてのインドール誘導体
JP2000007671A (ja) ２，３−ジヒドロベンゾフラン誘導体
MXPA05008437A (es) Derivados de benzofurano y el uso de los mismos como antidepresivos y ansioliticos.
US20060223824A1 (en) Serotonergic agents
CZ200077A3 (cs) Derivát piperazinu, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
KR20010112231A (ko) ５―ｈｔ 재흡수 저해제 및 ５―ｈｔ１ｂ／１ｄ리간드로서의 아미드 및 우레아 유도체
JPH06179685A (ja) ピロロチアゾールカルボキサミド誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100811

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100913

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101012

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110307

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110428

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140513

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees